{"id":"minoxidil-topical","safety":{"commonSideEffects":[{"rate":null,"effect":"Scalp irritation"},{"rate":null,"effect":"Dryness"},{"rate":null,"effect":"Itching"},{"rate":null,"effect":"Unwanted facial hair growth"},{"rate":null,"effect":"Contact dermatitis"}]},"_chembl":null,"_dailymed":{"setId":"4dc2850a-9a7e-660f-e063-6294a90afd94","title":"TACRUITF 5% MINOXIDIL WITH BIOTIN TOPICAL SOLUTION (MINOXIDIL) SOLUTION [GUANGZHOU BORDERLESS TECHNOLOGY CO., LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Minoxidil topical works by dilating blood vessels in the scalp, improving nutrient and oxygen delivery to hair follicles. It also directly stimulates hair follicle growth and extends the duration of the active growth phase, thereby increasing hair density and slowing hair loss. The exact molecular mechanism remains incompletely understood but involves potassium channel activation and potentially growth factor signaling.","oneSentence":"Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:35.993Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Androgenetic alopecia (male and female pattern hair loss)"}]},"trialDetails":[{"nctId":"NCT07435012","phase":"PHASE3","title":"Androgenic Alopecia TH07 Clinical Trial","status":"RECRUITING","sponsor":"Triple Hair Inc","startDate":"2026-04","conditions":"Androgenic Alopecia","enrollment":420},{"nctId":"NCT05417308","phase":"EARLY_PHASE1","title":"Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2023-03-01","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":50},{"nctId":"NCT07459933","phase":"PHASE4","title":"Topical Methotrexate vs Minoxidil for Localized Alopecia Areata","status":"NOT_YET_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2026-03-15","conditions":"Alopecia Areata","enrollment":268},{"nctId":"NCT07076706","phase":"PHASE2","title":"Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","startDate":"2024-12-05","conditions":"Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)","enrollment":110},{"nctId":"NCT07373054","phase":"NA","title":"Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-11-06","conditions":"Androgenic Alopecia","enrollment":18},{"nctId":"NCT07370519","phase":"PHASE2","title":"Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen People's Hospital","startDate":"2026-01-25","conditions":"Androgenetic Alopecia (AGA)","enrollment":388},{"nctId":"NCT07273799","phase":"PHASE3","title":"Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Federal Postgraduate Medical Institute","startDate":"2025-12-20","conditions":"Androgenic Alopecia","enrollment":200},{"nctId":"NCT04594018","phase":"PHASE3","title":"Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia","status":"RECRUITING","sponsor":"EMS","startDate":"2023-02-02","conditions":"Androgenetic Alopecia","enrollment":190},{"nctId":"NCT07264790","phase":"PHASE1","title":"Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2025-12","conditions":"Breast Reconstruction, Perfusion; Complications, High Risk for Breast Cancer","enrollment":25},{"nctId":"NCT07203599","phase":"PHASE1, PHASE2","title":"A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes","status":"RECRUITING","sponsor":"Shenzhen People's Hospital","startDate":"2025-09-20","conditions":"Androgenic Alopecia","enrollment":59},{"nctId":"NCT04207931","phase":"PHASE4","title":"Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-04-30","conditions":"Central Centrifugal Cicatricial Alopecia (CCCA)","enrollment":250},{"nctId":"NCT06556056","phase":"NA","title":"An Exploratory Clinical Study to Assess Safety, Efficacy and In-Use Tolerability of Three Different Hair Growth Products in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III)","status":"COMPLETED","sponsor":"NovoBliss Research Pvt Ltd","startDate":"2024-06-30","conditions":"Androgenic Alopecia","enrollment":108},{"nctId":"NCT06813963","phase":"PHASE4","title":"Minoxidil for Treating White Hair: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Southern Medical University, China","startDate":"2025-02-15","conditions":"Grey Hair","enrollment":100},{"nctId":"NCT04209803","phase":"PHASE4","title":"N-Acetyl-Cysteine for Treatment of AGA in Men","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2018-12-01","conditions":"Androgenetic Alopecia","enrollment":100},{"nctId":"NCT07012486","phase":"EARLY_PHASE1","title":"Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-06","conditions":"Androgenetic Alopecia (AGA)","enrollment":30},{"nctId":"NCT07011485","phase":"PHASE2","title":"A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.","status":"ACTIVE_NOT_RECRUITING","sponsor":"PDFE Pharma Innovations FZCO","startDate":"2025-05-14","conditions":"Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)","enrollment":15},{"nctId":"NCT04721548","phase":"PHASE3","title":"Treatment of Androgenetic Alopecia in Men for 24 Weeks","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2023-03-02","conditions":"Alopecia","enrollment":336},{"nctId":"NCT06826001","phase":"PHASE2","title":"Various Procedural Treatment Options for Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Medical College","startDate":"2025-02","conditions":"Androgenetic Alopecia","enrollment":190},{"nctId":"NCT06501924","phase":"PHASE3","title":"Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss","status":"NOT_YET_RECRUITING","sponsor":"Applied Biology, Inc.","startDate":"2025-01-15","conditions":"Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness","enrollment":516},{"nctId":"NCT06484881","phase":"PHASE3","title":"Clinical Study of Probiotic Treatment for Androgenetic Alopecia","status":"WITHDRAWN","sponsor":"Applied Biology, Inc.","startDate":"2024-09-15","conditions":"Androgenetic Alopecia, Female Pattern Baldness","enrollment":""},{"nctId":"NCT05888922","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Industrial Farmacéutica Cantabria, S.A.","startDate":"2024-09","conditions":"Androgenetic Alopecia, Female Pattern Baldness","enrollment":520},{"nctId":"NCT06015516","phase":"PHASE1","title":"Bioavailability Clinical Trial of Oral Minoxidil 1 mg","status":"COMPLETED","sponsor":"Industrial Farmacéutica Cantabria, S.A.","startDate":"2024-02-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT06552039","phase":"NA","title":"Proof-of-Science, Prospective, Interventional, Three-arm, Double-Blind, Randomized, Safety and Efficacy Real World Evidence Study.","status":"NOT_YET_RECRUITING","sponsor":"NovoBliss Research Pvt Ltd","startDate":"2024-08-24","conditions":"Hair Fall and Pre-mature Graying","enrollment":99},{"nctId":"NCT06527729","phase":"EARLY_PHASE1","title":"A Novel Formulation of Sildenafil-loaded Nanocarriers for Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Assiut University","startDate":"2021-07-01","conditions":"Alopecia Areata","enrollment":28},{"nctId":"NCT05636904","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men","status":"COMPLETED","sponsor":"Dermaliq Therapeutics, Inc.","startDate":"2022-12-05","conditions":"Androgenetic Alopecia","enrollment":120},{"nctId":"NCT06333600","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Topical Vitamin D Analogue in Treatment of Female Pattern Hair Loss","status":"RECRUITING","sponsor":"Sohag University","startDate":"2023-05-20","conditions":"Dermatology, Female Pattern Baldness","enrollment":45},{"nctId":"NCT06218394","phase":"NA","title":"Comparison of Microneedling vs. Autologous Concentrated Growth Factor for the Treatment of Female Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-12-14","conditions":"Androgenetic Alopecia","enrollment":135},{"nctId":"NCT06218498","phase":"NA","title":"Comparison of an Non-ablative Fractional 1565nm vs. an Ablative 2940-nm Fractional Er Laser for the Treatment of Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-11-24","conditions":"Androgenetic Alopecia","enrollment":135},{"nctId":"NCT06108193","phase":"PHASE1, PHASE2","title":"Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-07-11","conditions":"Acne Vulgaris","enrollment":26},{"nctId":"NCT06066827","phase":"NA","title":"Hair Regeneration in Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Dr. dr. Lili Legiawati, SpKK(K)","startDate":"2023-08-14","conditions":"Androgenetic Alopecia","enrollment":60},{"nctId":"NCT05989165","phase":"PHASE3","title":"Effectiveness of Combination Therapy of Microneedling and Minoxidil in Androgenetic Alopecia of Indonesian Men","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2023-06-01","conditions":"Androgenetic Alopecia","enrollment":36},{"nctId":"NCT05990400","phase":"PHASE2, PHASE3","title":"Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2023-05-01","conditions":"Androgenetic Alopecia","enrollment":40},{"nctId":"NCT06043349","phase":"PHASE4","title":"Effectiveness and Safety of Platelet-rich Plasma and Topical 5% Minoxidil Combination in Male Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2023-06-01","conditions":"Androgenetic Alopecia","enrollment":36},{"nctId":"NCT05864885","phase":"PHASE1","title":"Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Aneira Pharma, Inc.","startDate":"2023-06-09","conditions":"Androgenetic Alopecia","enrollment":14},{"nctId":"NCT05827991","phase":"NA","title":"A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-03-01","conditions":"Androgenic Alopecia","enrollment":75},{"nctId":"NCT05790941","phase":"EARLY_PHASE1","title":"Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation","status":"UNKNOWN","sponsor":"Aneira Pharma, Inc.","startDate":"2023-03-11","conditions":"Hypotrichosis","enrollment":12},{"nctId":"NCT04481412","phase":"PHASE2, PHASE3","title":"Topical Cetirizine in Androgenetic Alopecia in Females","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-07-25","conditions":"Androgenetic Alopecia","enrollment":66},{"nctId":"NCT04011748","phase":"PHASE2","title":"Clinical Application of Stem Cell Educator Therapy in Alopecia Areata","status":"UNKNOWN","sponsor":"Throne Biotechnologies Inc.","startDate":"2022-09-20","conditions":"Alopecia Areata, Alopecia Totalis, Alopecia Universalis","enrollment":20},{"nctId":"NCT05681897","phase":"NA","title":"Comparing Platelet-Rich Plasma (PRP) Centrifugation Methods on Thrombocyte Concentration and Clinical Improvement of Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2023-02","conditions":"Alopecia, Androgenetic","enrollment":30},{"nctId":"NCT05587257","phase":"NA","title":"Role of Minoxidil in Alopecia Areata Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Dioxide Laser or Microneedling Versus Its Topical Nanoparticles Preparation for Treatment of Alopecia Areata","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-01-01","conditions":"Alopecia Areata","enrollment":60},{"nctId":"NCT05409755","phase":"NA","title":"Radiofrequency in Female Pattern Hair Loss","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-06-25","conditions":"Female Pattern Baldness","enrollment":30},{"nctId":"NCT05369481","phase":"NA","title":"Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia","status":"UNKNOWN","sponsor":"Mohammed Abd El Mawgoud Amer","startDate":"2022-03-01","conditions":"Androgenic Alopecia","enrollment":50},{"nctId":"NCT01309191","phase":"NA","title":"Microarray Analysis of Scalp Biopsies After Minoxidil Treatment","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2011-04","conditions":"Androgenetic Alopecia","enrollment":14},{"nctId":"NCT05296863","phase":"PHASE3","title":"Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia","status":"COMPLETED","sponsor":"Dr. dr. Lili Legiawati, SpKK(K)","startDate":"2021-10-11","conditions":"Alopecia, Androgenetic, Hair Loss/Baldness","enrollment":37},{"nctId":"NCT03351322","phase":"PHASE2","title":"ENERGI-F701 for Female Hair Loss Treatment","status":"COMPLETED","sponsor":"Energenesis Biomedical Co., Ltd.","startDate":"2018-05-23","conditions":"Female Pattern Baldness, Hair Loss, Alopecia","enrollment":67},{"nctId":"NCT03488108","phase":"PHASE1, PHASE2","title":"Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-01-23","conditions":"Alopecia","enrollment":20},{"nctId":"NCT03753113","phase":"PHASE3","title":"Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%","status":"COMPLETED","sponsor":"Farid Masoud","startDate":"2018-11-28","conditions":"Androgenetic Alopecia","enrollment":24},{"nctId":"NCT04293822","phase":"PHASE4","title":"Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-06","conditions":"Androgenetic Alopecia","enrollment":60},{"nctId":"NCT03528772","phase":"NA","title":"Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2018-05-10","conditions":"Anal Fissure","enrollment":62},{"nctId":"NCT04090801","phase":"PHASE4","title":"Comparison of Topical Minoxidil 5% in Ethanol Plus Propylene Glycol Versus Minoxidil 5% in Ethanol Alone in Treatment of Women With Female Pattern Hair Loss","status":"COMPLETED","sponsor":"Sohag University","startDate":"2015-05-30","conditions":"Female Pattern Hair Loss","enrollment":60},{"nctId":"NCT02206802","phase":"","title":"Minoxidil Response Testing in Females With Female Pattern Hair Loss","status":"COMPLETED","sponsor":"Applied Biology, Inc.","startDate":"2014-07","conditions":"Alopecia, Female Pattern Hair Loss","enrollment":300},{"nctId":"NCT02198261","phase":"","title":"Minoxidil Response Testing in Males With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Applied Biology, Inc.","startDate":"2014-07","conditions":"Androgenetic Alopecia","enrollment":300},{"nctId":"NCT03535233","phase":"PHASE4","title":"Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2016-03","conditions":"Alopecia Areata","enrollment":40},{"nctId":"NCT02279823","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Intrepid Therapeutics, Inc.","startDate":"2014-10","conditions":"Androgenetic Alopecia","enrollment":95},{"nctId":"NCT00175617","phase":"PHASE2","title":"Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2005-09","conditions":"Female Pattern Hair Loss","enrollment":40},{"nctId":"NCT02486848","phase":"NA","title":"Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil","status":"WITHDRAWN","sponsor":"Maja Kovacevic, MD","startDate":"2016-06","conditions":"Female Pattern Hair Loss, Androgenetic Alopecia","enrollment":""},{"nctId":"NCT00151515","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"2003-10","conditions":"Androgenetic Alopecia","enrollment":352},{"nctId":"NCT02483195","phase":"PHASE4","title":"The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2016-08","conditions":"Female Androgenetic Alopecia","enrollment":""},{"nctId":"NCT02280603","phase":"PHASE1, PHASE2","title":"Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-01","conditions":"Androgenetic Alopecia","enrollment":60},{"nctId":"NCT01226459","phase":"PHASE3","title":"Clinical Trial in Females for Female Pattern Hair Loss","status":"COMPLETED","sponsor":"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","startDate":"2010-09","conditions":"Androgenetic Alopecia","enrollment":404},{"nctId":"NCT02154503","phase":"PHASE1","title":"Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Vancouver General Hospital","startDate":"2014-04","conditions":"Androgenetic Alopecia","enrollment":20},{"nctId":"NCT01145625","phase":"PHASE3","title":"Clinical Trial in Females With Female Pattern Hair Loss","status":"COMPLETED","sponsor":"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","startDate":"2010-06","conditions":"Alopecia","enrollment":322},{"nctId":"NCT01319370","phase":"PHASE2","title":"Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia","status":"COMPLETED","sponsor":"Natalie GARCIA BARTELS","startDate":"2010-11","conditions":"Androgenetic Alopecia","enrollment":70},{"nctId":"NCT01451125","phase":"PHASE2","title":"A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)","status":"COMPLETED","sponsor":"Aderans Research Institute","startDate":"2010-05","conditions":"Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness","enrollment":43},{"nctId":"NCT01391156","phase":"PHASE3","title":"Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss","status":"COMPLETED","sponsor":"Mae Fah Luang University Hospital","startDate":"2011-03","conditions":"Androgenetic Alopecia","enrollment":40},{"nctId":"NCT00958750","phase":"PHASE3","title":"Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2008-06","conditions":"Androgenetic Alopecia, Female Pattern Hair Loss","enrollment":113}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"ALOPECIA"},{"count":6,"reaction":"DRUG INEFFECTIVE"},{"count":5,"reaction":"PRODUCT USE ISSUE"},{"count":5,"reaction":"PRURITUS"},{"count":4,"reaction":"DIZZINESS"},{"count":3,"reaction":"CONDITION AGGRAVATED"},{"count":3,"reaction":"HEADACHE"},{"count":3,"reaction":"OFF LABEL USE"},{"count":3,"reaction":"PAIN"},{"count":3,"reaction":"SKIN IRRITATION"}],"_approvalHistory":[{"date":"20110428","type":"ORIG","sponsor":"PERRIGO PHARMA INTL","applicationNumber":"ANDA091344"},{"date":"20170303","type":"SUPPL","sponsor":"PERRIGO PHARMA INTL","applicationNumber":"ANDA091344"},{"date":"20161113","type":"SUPPL","sponsor":"PERRIGO PHARMA INTL","applicationNumber":"ANDA091344"},{"date":"20200610","type":"SUPPL","sponsor":"PERRIGO PHARMA INTL","applicationNumber":"ANDA091344"},{"date":"20071109","type":"ORIG","sponsor":"PURE SOURCE","applicationNumber":"ANDA078176"},{"date":"20160721","type":"SUPPL","sponsor":"PURE SOURCE","applicationNumber":"ANDA078176"},{"date":"20241126","type":"ORIG","sponsor":"TARO","applicationNumber":"ANDA218175"},{"date":"20160721","type":"SUPPL","sponsor":"PURE SOURCE","applicationNumber":"ANDA076239"},{"date":"20040824","type":"ORIG","sponsor":"PURE SOURCE","applicationNumber":"ANDA076239"},{"date":"20160721","type":"SUPPL","sponsor":"PURE SOURCE","applicationNumber":"ANDA076239"},{"date":"19990730","type":"ORIG","sponsor":"L PERRIGO CO","applicationNumber":"ANDA075357"},{"date":"20160330","type":"SUPPL","sponsor":"L PERRIGO CO","applicationNumber":"ANDA075357"},{"date":"20081008","type":"SUPPL","sponsor":"L PERRIGO CO","applicationNumber":"ANDA075357"},{"date":"20050714","type":"SUPPL","sponsor":"L PERRIGO CO","applicationNumber":"ANDA075357"}],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Minoxidil Topical","genericName":"Minoxidil Topical","companyName":"Dr. dr. Lili Legiawati, SpKK(K)","companyId":"dr-dr-lili-legiawati-spkk-k","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Minoxidil Topical is used to treat conditions such as Androgenetic Alopecia, Female Pattern Hair Loss, and Alopecia Areata, as well as Vitiligo - Macular Depigmentation. It works by opening the Sulfonylurea receptor 2, Kir6.2, which is a mechanism classified as a small molecule opener.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-07-30T00:00:00.000Z","mah":"L PERRIGO CO","brand_name_local":null,"application_number":"ANDA075357"},{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"2004-08-24T00:00:00.000Z","mah":"PURE SOURCE","brand_name_local":null,"application_number":"ANDA076239"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-11-09T00:00:00.000Z","mah":"PURE SOURCE","brand_name_local":null,"application_number":"ANDA078176"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-04-28T00:00:00.000Z","mah":"PERRIGO PHARMA INTL","brand_name_local":null,"application_number":"ANDA091344"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-11-26T00:00:00.000Z","mah":"TARO","brand_name_local":null,"application_number":"ANDA218175"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}